Randomized controlled 12 months trial with etanercept (enbrel) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER).

Trial Profile

Randomized controlled 12 months trial with etanercept (enbrel) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Etanercept (Primary) ; Sulfasalazine
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms ESTHER
  • Most Recent Events

    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 Oct 2013 Results of an analysis of osteitis after 3 years of etanercept therapy (n=40) presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 Oct 2013 Results of an anaylsis of patients who received 3 years of etanercept (n=60) presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top